通过分析美国近期发生的“Lilly vs Teva”生物医药专利重复授权纠纷案,深入研究美国专利重复授权的审查标准,在此基础上讨论我国目前重复授权的审查标准,指出存在的问题及可能带来的一些不利影响。最后结合美国重复授权审查标准,对我国重复授权审查标准的完善提出建议。 By analyzing the recent “Lilly vs Teva” biopharmaceutical patent duplication licensing case in the United States, this paper delves into the review criteria of the U.S. patent duplicate authorization, and on this basis, discusses the current re-authorization review standards in China, points out the existing problems and possible Some negative effects. Finally, combined with the United States repeated authorization review standards, the review of China’s repeated authorization standards to make recommendations.